Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

BACKGROUND Uncertainty about prognosis and treatment of axillary lymph node-negative patients with estrogen receptor (ER)-negative or ER-positive invasive breast tumors of 1 cm or less prompted the analysis of data from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. METHODS Two hundred thirty-five patients with ER-negative tumors and 1024 patients with ER-positive tumors were identified in these trials. Patients with ER-negative tumors received surgery alone or surgery and chemotherapy. Patients with ER-positive tumors received surgery alone; surgery and tamoxifen; or surgery, tamoxifen, and chemotherapy. End points were relapse-free survival (RFS), event-free survival, and overall survival. A result was considered to be statistically significant with a P value of.05 or less; all statistical tests were two-sided. RESULTS The 8-year RFS of women with ER-negative tumors who received surgery alone or with chemotherapy was 81% and 90%, respectively (P = .06). Survival was similar in both groups (93% and 91%; P = .65). The 8-year RFS of women with ER-positive tumors was 86% after surgery alone, 93% when tamoxifen was added (P = .01), and 95% after the addition of tamoxifen and chemotherapy (P = .07 compared with tamoxifen). Survival in the three groups was 90%, 92% (P = .41), and 97%, respectively. The difference between the latter two groups was significant (P = .01). Regardless of ER status or treatment, overall mortality was 8%; one half of the deaths were related to breast cancer. Several covariates affected the risk of recurrence in ER-negative and ER-positive patients. Risk was greater in women with tumors of 1 cm than in those with tumors of less than 1 cm, in women aged 49 years or younger than in those aged 50 years or older, and in women with infiltrating ductal or lobular carcinoma than in those with other histologic tumor types. CONCLUSIONS Chemotherapy and/or tamoxifen should be considered for the treatment of women with ER-negative or ER-positive tumors of 1 cm or less and negative axillary lymph nodes.

[1]  H. Joensuu,et al.  Late mortality from pT1N0M0 breast carcinoma , 1999, Cancer.

[2]  S. Schnitt,et al.  Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma , 1998, Cancer.

[3]  B Fisher,et al.  Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.

[4]  O. Gröntoft,et al.  Histopathology grading in small brast cancers ≤ 10mm – results from an area with mammography screening , 1997, Breast cancer research and treatment.

[5]  M. Loda,et al.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.

[6]  M. Loda,et al.  Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0) , 1997 .

[7]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[8]  C. Redmond,et al.  Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Gelber,et al.  Meeting highlights: international consensus panel on the treatment of primary breast cancer. , 2002, Journal of the National Cancer Institute.

[10]  R. Hutter,et al.  Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T 1 a,b NO MO) , 1995 .

[11]  C. Redmond,et al.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. , 1995, New England Journal of Medicine.

[12]  J. Wittliff,et al.  Influence of Biopsy Size on Sex‐Steroid Receptor Levels Determined by Enzyme Immunoassay , 1995 .

[13]  S Hellman,et al.  Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Fagerberg,et al.  Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening. , 1994, The European journal of surgery = Acta chirurgica.

[15]  L. Norton,et al.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jeffrey J. Gaynor,et al.  On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .

[17]  G. Kornek,et al.  Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. , 1992, Surgery, gynecology & obstetrics.

[18]  J. Crowe,et al.  Primary tumor size. Relevance to breast cancer survival. , 1992, Archives of surgery.

[19]  W. Lane,et al.  Should all patients with node‐negative breast cancer receive adjuvant therapy? Identifying additional subsets of low‐risk patients who are highly curable by surgery alone , 1991, Cancer.

[20]  S. Groshen,et al.  Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0). Assessment of 644 patients with median follow-up of 18 years. , 1990, The Surgical clinics of North America.

[21]  W. Lane,et al.  Node‐negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy , 1990, Cancer.

[22]  C K Osborne,et al.  Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.

[23]  C. Redmond,et al.  A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. , 1989, The New England journal of medicine.

[24]  J. Hendriks,et al.  Treatment and Survival of Female Patients with Nonpalpable Breast Carcinoma , 1989, Annals of surgery.

[25]  T. Powles,et al.  Development and Use of a Natural History Data Base of Breast Cancer Studies , 1987, American journal of clinical oncology.

[26]  G. Bonadonna,et al.  Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.

[27]  B Fisher,et al.  Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.

[28]  J. Wittliff,et al.  Methods of steroid receptor analyses and their quality control in the clinical laboratory. , 1981, Progress in clinical and biological research.

[29]  P. Saigo,et al.  Predictors of recurrence in stage I (T1N0M0) breast carcinoma. , 1981, Annals of surgery.

[30]  G. Bonadonna.  ADJUVANT CHEMOTHERAPY FOR BREAST CANCER , 1979, The Lancet.

[31]  J. Tata,et al.  Steroid hormone receptors , 1978, Nature.

[32]  C. Redmond,et al.  L‐phenylalanine mustard (L‐PAM) in the management of primary breast cancer: An update of earlier findings and a comparison with those utilizing L‐PAM plus 5‐fluorouracil (5‐FU) , 1977, Cancer.

[33]  G. Bonadonna,et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.

[34]  N. Wolmark,et al.  Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. , 1975, Surgery, gynecology & obstetrics.

[35]  C. Redmond,et al.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.

[36]  I D Bross,et al.  Cancer of the breast: Size of neoplasm and prognosis , 1969, Cancer.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  D.,et al.  Regression Models and Life-Tables , 2022 .